The PlaqueTec team includes internationally recognised cardiovascular scientists and physicians. For more information about the leadership and scientific advisory board, please see below.
BOARD OF DIRECTORS & ADVISERS
Chairman of the Board
Martin Stapleton is Chairman of the board of directors of PlaqueTec. He is the joint principal of Ipex Capital with Jon Moynihan. Martin has been spinning out IP from corporates and managing venture funds since the 1990s. Prior to establishing Ipex Capital out of PA Consulting in 2008, Martin also spun out TIBCO Software (TIBX) and Reuters Venture Capital (RVC) from Reuters. Successful exits include Medsite, UltraDNS, Radialpoint, Visible World and Procserve.
Chief Financial Officer and Board Member
Chris Haynes has extensive experience serving as CFO and board member for a number of technology companies in a wide range of disciplines, such as consumer electronics, medtech, software and services businesses. He has led multiple successful fundraising rounds, complex company structuring projects, and successful exits of venture backed technology companies. Chris is also CFO and Partner of Ipex Capital, where he is responsible for all financial and tax planning, as well as portfolio company management. He is also responsible for deal planning, execution, and managing external relationships with advisers. Chris qualified as an ACA with Ernst & Young.
SIMON WILLIAMS MBBS MRCS MFPM
General Manager and Board Member
Dr Simon Williams has day-to-day responsibility for PlaqueTec’s ongoing clinical, research and operational activities, and manages PlaqueTec’s external collaborations. Initially pursuing a career in surgery, Simon changed tack and joined the biopharmaceutical industry in 2010 where he has gained experience supporting the late stage development and commercialisation of numerous assets in various therapeutic areas. Most recently his focus was in the cardiovascular space as a Medical Director at Amgen, where he played a key role in the PCSK9 inhibitor programme in the UK and Ireland as the medical lead for all pre and post launch activities for this breakthrough compound.
DIANE PROUDFOOT PhD
Chief Scientific Officer
Dr Proudfoot has over 25 years of experience in cardiovascular research with particular focus on vascular smooth muscle cells and markers of cardiovascular disease. Prior to joining PlaqueTec as Head of Cardiovascular Research in February 2018, Dr. Proudfoot held a British Heart Foundation Career Re-entry Fellowship at the Babraham Institute (Cambridge UK), investigating the impact of microcalcification on human vascular smooth muscle cell function. She has developed extensive knowledge in the field of vascular calcification and has won a number of investigator awards including a British Heart Foundation Intermediate Fellowship, based at the Department of Medicine, University of Cambridge, working on mechanisms that initiate and regulate the formation of calcified deposits in arteries. Dr. Proudfoot has a PhD focusing on cell interactions in atherosclerosis (University of Cambridge), and a degree in Biochemistry and Pharmacology (University of Strathclyde). Diane has over 30 peer reviewed publications in the field of cardiovascular research, and is currently a member of the British Atherosclerosis Society, the Biochemical Society and the Physiological Society.
SCIENTIFIC ADVISORY BOARD